RxDoctor Payments DataLook up a doctor →

Alan Wynne, MD

Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1952481145

Payments from drug & device makers

$6,886,292in general payments, 2019–2025

Across 2,864 payments — averaging $2404.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$4.6M
  • Novo Nordisk AS$1.5M
  • AbbVie$261K
  • Pfizer$167K
  • Sanofi US Services Inc.$121K
  • AstraZeneca$85K
  • plus $142K from 16 others
$44,793in research payments, 2019–2025

Across 19 payments — averaging $2357.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$45K

What the payments were for

  • Consulting fees$2,92538%
  • Travel & lodging$3,72748%
  • Food & beverage$98913%
  • Education$731%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,886,292 in reported general payments places this provider in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

See all endocrinology, diabetes & metabolism providers in Kansas

Medicare billing

Part B allowed, 2024
$28,565
Medicare patients
201
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$26,116
Novolog FlexpenInsulin Aspart12$3,928
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$1,771
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,572
Levothyroxine Sodium50$542
Atorvastatin Calcium13$206
Glimepiride24$176
Metformin Hcl ErMetformin Hcl25$173
Pioglitazone Hcl11$143
Methimazole12$113
Metformin Hcl17$68
Glipizide11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$131$26,11612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

Other endocrinology, diabetes & metabolism in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →